In this study, we observed that CUMS or CUMS-FMT could lead to the disruption of colonic barrier function, production of colonic inflammation, and elevation of serum proinflammatory cytokines IL-6, IL-1β, and TNF-α, whereas XYS-FMT can restore intestinal barrier function and inhibit colon inflammation and inflammatory factors in sera. This evidence concerns the gene IL6 and colitis.